Manila Bulletin

Garin drags Ona into dengue vaccine controvers­y

- By CHARINA L. ECHALUCE

After drawing the flak over the government’s dengue immunizati­on program, former Health Secretary Janette Garin has implicated her predecesso­r, former Health Secretary Enrique Ona, in the now controvers­ial vaccinatio­n activity.

In a television (ANC) interview, Garin said the program, which used the anti-dengue vaccine Dengvaxia, was not her decision alone as it was the initiative of Ona way back in 2010. At that time, Garin said, Sanofi Pasteur’s Dengvaxia was the one being considered.

“Hindi po ito decision na ako lang. Hindi po ito sinimulan lang noong pagpasok ko noong 2014. I think June or July, Secretary Ona already announced na magkakaroo­n ng bakunang dengue by 2015, probably middle, and the department is contemplat­ing on putting it in their public health program, perosinabi rin niya na wala pa 'yung presyo at di pa napag-uusapan (This is not my decision alone. This did not start when I became the DOH chief in 2014. I think June or July, Secre-

tary Ona already announced that there will an anti-dengue vaccinatio­n by 2015, probably middle, and the department is contemplat­ing on putting it in their public health program, but he revealed then that there’s no price and negotiatio­n yet),” she said.

“It started during his time,” she maintained.

Former Secretary Ona could not be reached for comment. As of press time, he has not responded to text messages.

Over 830,000 children have already received at least one dose of the vaccine under the government’s immunizati­on program.

But last November 30, Sanofi Pasteur disclosed that Dengvaxia was found to potentiall­y cause increased risk of hospitaliz­ation for dengue and severe dengue for those who have not yet infected by the virus.

“The analysis confirmed that Dengvaxia provides persistent protective benefit against dengue fever in those who had prior infection... For those not previously infected by dengue virus, however, the analysis found that in the longer term, more cases of severe disease could occur following vaccinatio­n upon a subsequent dengue infection,”Sanofi said in a statement.

Dengvaxia, the first dengue vaccine to be licensed after being approved in Mexico back in December 2015, was used in the DOH’s immunizati­on drive.

But after Sanofi’s announceme­nt, Health Secretary Francisco Duque III suspended the government dengue vaccinatio­n program.

Garin said she and her child were even vaccinated using Dengvaxia, which was said to be effective to people aged nine years old to 45 years old.

“Kahit kami, galit na galit kami nang malaman naming ang announceme­nt ng Sanofi lalo na noong makita mo severe dengue. Nanay din ako.Anak ko nabakunaha­n din. Ako nabakunaha­n din (We are very angry, too, after hearing Sanofi’s announceme­nt, especially when we found out that it will cause severe dengue. I’m a mother, too. My child was also vaccinated. I was vaccinated, as well),” she said.

 ??  ?? DENGUE PREVENTION – As a family looks on, a worker uses a defogging machine to eliminate adult mosquitoes, which could be the source of the dengue virus in this community on Sto. Niño St. in Barangary 177, Maligaya, Caloocan City. (Mark Balmores)
DENGUE PREVENTION – As a family looks on, a worker uses a defogging machine to eliminate adult mosquitoes, which could be the source of the dengue virus in this community on Sto. Niño St. in Barangary 177, Maligaya, Caloocan City. (Mark Balmores)

Newspapers in English

Newspapers from Philippines